Improving Collection and Analysis of Overall Survival Data
Authors:
- Lisa R. RodriguezLRLisa R. Rodriguez
- Nicole J. GormleyNGNicole J. Gormley
- Ruixiao LuRLRuixiao Lu
- Anup K. AmatyaAAAnup K. Amatya
- George D. DemetriGDGeorge D. Demetri
- Keith T. FlahertyKFKeith T. Flaherty
- Ruben A. MesaRMRuben A. Mesa
- Richard PazdurRPRichard Pazdur
- Mikkael A. SekeresMSMikkael A. Sekeres
- Minghua ShanMSMinghua Shan
- Steven SnapinnSSSteven Snapinn
- Marc R. TheoretMTMarc R. Theoret
Open Access
- 17 July 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (18) , 3974-3982
Abstract
Advances in anticancer therapies have provided crucial benefits for millions of patients who are living long and fulfilling lives. Although these successes should be celebrated, there is certainly room to continue improving cancer care. Increased long-term survival presents additional challenges for determining whether new therapies further extend patients’ lives through clinical trials, commonly known as the gold standard endpoint of overall survival (OS). As a result, an increasing reliance is observed on earlier efficacy endpoints, which may or may not correlate with OS, to continue the timely pace of translating innovation into novel therapies available for patients. Even when not powered as an efficacy endpoint, OS remains a critical indication of safety for regulatory decisions and is a key aspect of the FDA’s Project Endpoint. Unfortunately, in the pursuit of earlier endpoints, many registrational clinical trials lack adequate planning, collection, and analysis of OS data, which complicates interpretation of a net clinical benefit or harm. This article shares best practices, proposes novel statistical methodologies, and provides detailed recommendations to improve the rigor of using OS data to inform benefit–risk assessments, including incorporating the following in clinical trials intending to demonstrate the safety and effectiveness of cancer therapy: prospective collection of OS data, establishment of fit-for-purpose definitions of OS detriment, and prespecification of analysis plans for using OS data to evaluate for potential harm. These improvements hold promise to help regulators, patients, and providers better understand the benefits and risks of novel therapies.Keywords
Funding Information
- U.S. Food and Drug Administration
This publication has 24 references indexed in Scilit:
- A promising biomarker adaptive Phase 2/3 design – Explained and expandedContemporary Clinical Trials Communications, 2023
- Treatment effect measures under nonproportional hazardsPharmaceutical Statistics, 2022
- Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling frameworkCPT: Pharmacometrics & Systems Pharmacology, 2021
- Optimizing subgroup selection in two‐stage adaptive enrichment and umbrella designsStatistics in Medicine, 2021
- Multiplicity for a group sequential trial with biomarker subpopulationsContemporary Clinical Trials, 2021
- Adaptive expansion of biomarker populations in phase 3 clinical trialsContemporary Clinical Trials, 2018
- Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in GermanyValue in Health, 2018
- TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALSInternational Journal of Technology Assessment in Health Care, 2016
- Sensitivity analysis for missing data in regulatory submissionsStatistics in Medicine, 2015
- Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical TrialsClinical Pharmacology & Therapeutics, 2014